Subject(s)
Androstanes/pharmacology , Neuromuscular Junction/drug effects , Neuromuscular Nondepolarizing Agents/pharmacology , Acetylcholine/administration & dosage , Acetylcholine/pharmacology , Action Potentials/drug effects , Animals , Anura , Bromides/pharmacology , Dose-Response Relationship, Drug , Drug Synergism , In Vitro Techniques , Iontophoresis , Microelectrodes , Muscles/drug effects , Pancuronium/administration & dosage , Pancuronium/pharmacology , Rana pipiens , Sciatic Nerve/drug effects , Tetany/chemically inducedSubject(s)
Nerve Block/methods , Neuromuscular Junction/drug effects , Succinylcholine/administration & dosage , Atracurium , Dose-Response Relationship, Drug , Humans , Injections, Intravenous , Intubation, Intratracheal , Isoquinolines/administration & dosage , Pancuronium/administration & dosage , Pancuronium/analogs & derivatives , Vecuronium BromideABSTRACT
In vivo, the effects of d-tubocurarine (0.20 mg kg-1), pancuronium (0.015 mg kg-1) and atracurium (0.15 mg kg-1) on the responses of the indirectly stimulated cat gastrocnemius (fast) and soleus (slow) muscles to a twitch, train-of-four and tetanic stimuli were studied. The soleus muscle demonstrated a greater degree of fade than the gastrocnemius in response to tetanic stimuli (50 Hz). There was no difference between the responses of the two muscles to twitch or train-of-four stimuli with any of the drugs. Recovery of train-of-four ratio occurred more rapidly than did the tetanic fade ratio. At a time when train-of-four ratio exceeded 0.7, tetanic fade was still evident, especially in the soleus muscle.
Subject(s)
Isoquinolines/pharmacology , Neuromuscular Blocking Agents/pharmacology , Neuromuscular Junction/drug effects , Pancuronium/pharmacology , Tubocurarine/pharmacology , Animals , Atracurium , Cats , Electric Stimulation , In Vitro Techniques , Muscle Contraction/drug effects , Muscles/innervation , Tetany/etiology , Time FactorsABSTRACT
The time of onset and degree of neuromuscular blockade (NMB) in 80 anaesthetized patients, following either a single bolus injection of pancuronium 0.95 mg kg-1, atracurium 0.53 mg kg-1 or vecuronium 0.07 mg kg-1, or divided doses of pancuronium 0.15 mg kg-1, atracurium 0.07 mg kg-1 or vecuronium 0.01 mg kg-1 administered 3 min or 5 min before the second dose of pancuronium 0.08 mg kg-1, atracurium 0.46 mg kg-1 or vecuronium 0.06 mg kg-1, were determined and compared to the same parameters measured following succinylcholine administration (1 mg kg-1). The time to maximum NMB (100%) following the administration of succinylcholine was 58.1 +/- 5.3 s, whereas the time to maximum NMB (100%) following a single bolus injection of either pancuronium, atracurium or vecuronium was 130.6 +/- 22.2, 93.0 +/- 6.4, 127.5 +/- 13.0 s, respectively. These values for time to maximum NMB are significantly longer than the time required for succinylcholine to achieve maximal blockade. The time to attain maximum NMB following divided doses of pancuronium, atracurium or vecuronium separated by 3 min decreased significantly to 77.9 +/- 4.3, 77.5 +/- 7.6, 89.0 +/- 8.6 s, respectively. However, when the two doses of drug were separated by 5 min, only small, non-significant further decreases occurred in the time required to achieve maximum blockade. Although the time to maximum NMB following divided doses of pancuronium, atracurium or vecuronium is significantly longer than that for succinylcholine, divided dosing significantly decreases the time required to reach maximal NMB.
Subject(s)
Atracurium/pharmacology , Neuromuscular Junction/drug effects , Pancuronium/pharmacology , Succinylcholine/pharmacology , Vecuronium Bromide/pharmacology , Adolescent , Adult , Humans , Middle Aged , Time FactorsABSTRACT
The authors sought to determine whether prior administration of a small, subparalyzing dose of nondepolarizing muscle relaxant would shorten the onset time of an intubating dose of muscle relaxant. Initially, in 60 anesthetized patients, twitch response of adductor pollicis to ulnar nerve stimulation was studied after a small dose of pancuronium 0.015 mg . kg-1, metocurine 0.03 mg . kg-1, or d-tubocurarine 0.04 mg . kg-1, followed 3 min later by pancuronium 0.08 mg . kg-1 or atracurium 0.4 mg . kg-1 administered iv. After 60 s, the minimum neuromuscular block, in all patients was 79.0 +/- 5.0%. A 95% depression or twitch tension occurred between 59.1 +/- 5.3 and 86.1 +/- 5.9 s. In another 60 patients, intubating conditions under similar regimen were studied, except the small dose of muscle relaxant was given immediately prior to induction of anesthesia. At the end of 60 s, good to excellent intubating conditions were present in 100% of the patients following the second dose of pancuronium and in 83% of the patients following atracurium. In 17% of the patients, after atracurium intubating conditions were fair. When nondepolarizing neuromuscular blocking drugs are administered in divided doses, neuromuscular blockade adequate for endotracheal intubation is achieved in less than 90 s. This facilitates rapid endotracheal intubation in a time comparable to using succinylcholine, without undesirable effects of the depolarizing neuromuscular blocking drugs.
Subject(s)
Intubation, Intratracheal , Neuromuscular Nondepolarizing Agents/administration & dosage , Adolescent , Adult , Anesthesia, General , Atracurium , Drug Administration Schedule , Humans , Isoquinolines/administration & dosage , Middle Aged , Muscle Contraction/drug effects , Pancuronium/administration & dosage , Time Factors , Tubocurarine/administration & dosage , Tubocurarine/analogs & derivativesABSTRACT
The purpose of this study was to evaluate neuromuscular and cardiovascular effects of doxacurium chloride, a new long-acting neuromuscular blocking agent, during a stable state of nitrous oxide and narcotic anesthesia. Ninety-three ASA physical status I or II patients were studied after informed written consent had been obtained. Eighty-one patients (group A) received doxacurium. The 81 patients were divided into nine subgroups according to the dose of doxacurium administered (0.01-0.06 mg.kg-1). Patients in a control group (group B) (n = 12) received pancuronium. To assess neuromuscular responses, a force displacement transducer recorded the twitch response of the adductor pollicis muscle following ulnar nerve stimulation. The ED50 and ED95 for doxacurium were estimated to be 0.013 mg.kg-1 and 0.023 mg.kg-1, respectively. The time to maximum twitch suppression following a dose of 1.0 (ED95) and 1.7 (ED95) was 10.3 +/- 1.3 min and 7.6 +/- 0.8 min, respectively. After an ED95 dose of doxacurium the time to spontaneous recovery to 95% of control twitch height was 73.7 +/- 8.7 min. With larger doses of doxacurium, 0.04 mg.kg-1 (1.7 X ED95) and 0.05 mg.kg-1 (2.2 X ED95), the time to spontaneous recovery to 95% of control twitch height was 125.8 +/- 24.8 and 204.0 +/- 21.2 minutes, respectively. When 25% twitch height recovery or more was present the reversal of doxacurium induced neuromuscular blockade was prompt.(ABSTRACT TRUNCATED AT 250 WORDS)